Aslan Gets Singapore Nod For Initial Trial Of RA Candidate From Spain’s Almirall
This article was originally published in PharmAsia News
Aslan Pharmaceuticals received approval for a Phase I clinical trial of a rheumatoid arthritis DHODH inhibitor by Singapore’s Health Sciences Authority and will work with CRO Quintiles at Changi General Hospital.
You may also be interested in...
Bristol-Myers Squibb Co. has formed a partnership with Singapore-based ASLAN Pharmaceuticals Pte. Ltd. to hasten the development of an early-stage compound that it considers promising, but not core to the big pharma's focus on more advanced oncology compounds
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.
Southeast Asia in 2014 saw a continued push by several nations in the region to ink a Trans-Pacific Partnership pact that would potentially have a major impact on biological drugs. Also manufacturing and distribution saw a leap in the hub of Singapore as governments in the region ramped-up health spending.